

# Demei Zhu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1044634/publications.pdf>

Version: 2024-02-01

35  
papers

997  
citations

623188

14  
h-index

476904

29  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1165  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Status and Trends of Antibacterial Resistance in China. <i>Clinical Infectious Diseases</i> , 2018, 67, S128-S134.	2.9	205
2	Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 2275-2281.	1.3	185
3	Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the <i>In Vitro</i> Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	78
4	Mechanisms of Tigecycline Resistance among <i>Klebsiella pneumoniae</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6982-6985.	1.4	71
5	Emergence of carbapenem-resistant clinical <i>Enterobacteriaceae</i> isolates from a teaching hospital in Shanghai, China. <i>Journal of Medical Microbiology</i> , 2012, 61, 132-136.	0.7	56
6	<i>In Vitro</i> Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of <i>Enterobacteriales</i> , <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> : Results from China Antimicrobial Surveillance Network (CHINET) in 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	38
7	In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Resistance and Infection Control</i> , 2018, 7, 142.	1.5	36
8	High Prevalence of <i>vanM</i> in Vancomycin-Resistant <i>Enterococcus faecium</i> Isolates from Shanghai, China. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7795-7798.	1.4	34
9	Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 35-44.	1.5	33
10	Hospital clonal dissemination of <i>Enterobacter aerogenes</i> producing carbapenemase KPC-2 in a Chinese teaching hospital. <i>Journal of Medical Microbiology</i> , 2014, 63, 222-228.	0.7	29
11	Prevalence of the fosfomycin-resistance determinant, <i>fosB3</i> , in <i>Enterococcus faecium</i> clinical isolates from China. <i>Journal of Medical Microbiology</i> , 2014, 63, 1484-1489.	0.7	26
12	A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia. <i>Journal of Microbiology, Immunology and Infection</i> , 2017, 50, 811-820.	1.5	26
13	Clonal dissemination of extensively drug-resistant <i>Acinetobacter baumannii</i> producing an OXA-23 $\beta$ -lactamase at a teaching hospital in Shanghai, China. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 101-108.	1.5	22
14	CHINET efforts to control antimicrobial resistance in China. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 76-77.	0.9	19
15	Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis. <i>Clinical Therapeutics</i> , 2019, 41, 1164-1174.e4.	1.1	18
16	Comparison of Four Carbapenemase Detection Methods for <i>bla</i> KPC-2 Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0095421.	1.2	14
17	Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 514-519.	1.1	13
18	<i>Klebsiella pneumoniae</i> : Development of Carbapenem Resistance due to Acquisition of <i>bla</i> NDM-1 During Antimicrobial Therapy in Twin Infants with Pneumonia. <i>Frontiers in Microbiology</i> , 2015, 6, 1399.	1.5	13

#	ARTICLE	IF	CITATIONS
19	<i>In Vitro</i> Activity of New $\beta$ -Lactam- $\beta$ -Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	12
20	In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1559-1572.	1.3	11
21	Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis. <i>Future Microbiology</i> , 2017, 12, 39-50.	1.0	10
22	A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2327-2339.	0.9	10
23	In vitro bactericidal property of levornidazole against <i>Bacteroides fragilis</i> studied by time-kill assay and sigmoid E max model analysis. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 673-675.	1.1	7
24	In vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017-2019. <i>Frontiers in Microbiology</i> , 2020, 11, 578824.	1.5	6
25	A Case-Control Study: Clinical Characteristics of Nosocomial Bloodstream Infections Versus Non-bloodstream Infections of <i>Acinetobacter</i> spp.. <i>Clinical Infectious Diseases</i> , 2018, 67, S189-S195.	2.9	4
26	Comparative In Vitro Activities of Ceftaroline and Tedizolid against Clinical Strains of <i>Staphylococcus aureus</i> and <i>Enterococcus</i> : Results from the China Antimicrobial Surveillance Network (CHINET) in 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
27	A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia. <i>Current Medical Research and Opinion</i> , 2021, 37, 693-701.	0.9	4
28	Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2271-2283.	1.3	4
29	Assessment of Ceftazidime-Avibactam 30/20- $\beta$ Disk, Etest versus Broth Microdilution Results When Tested against <i>Enterobacterales</i> Clinical Isolates. <i>Microbiology Spectrum</i> , 2022, 10, e0109221.	1.2	4
30	Study of <i>In Vitro</i> Synergistic Bactericidal Activity of Dual $\beta$ -Lactam Antibiotics Against KPC-2-Producing <i>Klebsiella pneumoniae</i> . <i>Microbial Drug Resistance</i> , 2020, 26, 204-210.	0.9	2
31	In Vitro Activity of KBP-7072 against 536 <i>Acinetobacter baumannii</i> Complex Isolates Collected in China. <i>Microbiology Spectrum</i> , 2022, , e0147121.	1.2	2
32	697. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06). <i>Open Forum Infectious Diseases</i> , 2019, 6, S315-S315.	0.4	1
33	2478. Surveillance of antibacterial resistance among clinical isolates from hospitals in Shanghai: results of 2018. <i>Open Forum Infectious Diseases</i> , 2019, 6, S858-S858.	0.4	0
34	576. A Multicenter Epidemiology Study on Risk Factors of Vancomycin-Resistant <i>Enterococcus</i> Infections in China: Results from the China Antimicrobial Surveillance Network (CHINET) in 2016. <i>Open Forum Infectious Diseases</i> , 2019, 6, S271-S272.	0.4	0
35	686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06). <i>Open Forum Infectious Diseases</i> , 2019, 6, S312-S312.	0.4	0